Alli Return In U.S. Fattens Glaxo’s Consumer Outlook
This article was originally published in The Pink Sheet Daily
GSK Consumer Healthcare says alli would be available starting Feb. 25 in most stores in the U.S. and Puerto Rico in “improved tamper-evident packaging.” Despite the product’s checkered history, its return marks another boost for Glaxo’s consumer outlook.
You may also be interested in...
With more than two years of competition behind them, it’s becoming clear that latecomer Contrave might just be the star of the obesity drug market, while its competitors are stuck playing second fiddle. Yet, all players are benefiting from increased obesity sales reps in the field.
GSK investigates tampering with its alli weight-loss drug and positions itself as a consumer advocate with a U.S. recall of the product. By showing it is “on the side of good” the firm could actually emerge from the crisis with a stronger reputation, says crisis management expert Gene Grabowski says.
GlaxoSmithKline abandons its attempt to divest the OTC weight loss aid alli, even though the beleaguered brand continues to drag down consumer division sales. The division’s sales climbed 7% excluding alli in the firm’s second quarter, but only 5% including the product’s results.